BG63126B1 - Лечебни препарати на основата на нуклеинови киселини - Google Patents
Лечебни препарати на основата на нуклеинови киселини Download PDFInfo
- Publication number
- BG63126B1 BG63126B1 BG100006A BG10000695A BG63126B1 BG 63126 B1 BG63126 B1 BG 63126B1 BG 100006 A BG100006 A BG 100006A BG 10000695 A BG10000695 A BG 10000695A BG 63126 B1 BG63126 B1 BG 63126B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- seq
- dna
- gene
- influenza
- vijns
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims description 76
- 102000039446 nucleic acids Human genes 0.000 title claims description 74
- 108020004707 nucleic acids Proteins 0.000 title claims description 74
- 238000002360 preparation method Methods 0.000 title description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 212
- 241000700605 Viruses Species 0.000 claims abstract description 84
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 80
- 208000015181 infectious disease Diseases 0.000 claims abstract description 75
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 69
- 241001465754 Metazoa Species 0.000 claims abstract description 60
- 230000004224 protection Effects 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 12
- 206010022000 influenza Diseases 0.000 claims description 116
- 108010061100 Nucleoproteins Proteins 0.000 claims description 96
- 229960005486 vaccine Drugs 0.000 claims description 96
- 102000011931 Nucleoproteins Human genes 0.000 claims description 94
- 239000013598 vector Substances 0.000 claims description 89
- 101710154606 Hemagglutinin Proteins 0.000 claims description 84
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 84
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 84
- 101710176177 Protein A56 Proteins 0.000 claims description 84
- 239000000185 hemagglutinin Substances 0.000 claims description 77
- 210000004027 cell Anatomy 0.000 claims description 71
- 230000003612 virological effect Effects 0.000 claims description 58
- 230000003053 immunization Effects 0.000 claims description 49
- 238000002649 immunization Methods 0.000 claims description 48
- 230000028993 immune response Effects 0.000 claims description 45
- 230000004044 response Effects 0.000 claims description 45
- 239000013612 plasmid Substances 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 42
- 230000014509 gene expression Effects 0.000 claims description 41
- 241000845082 Panama Species 0.000 claims description 36
- 239000013604 expression vector Substances 0.000 claims description 25
- 230000001681 protective effect Effects 0.000 claims description 23
- 230000003472 neutralizing effect Effects 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 230000000890 antigenic effect Effects 0.000 claims description 16
- 238000010276 construction Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 238000002255 vaccination Methods 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 238000010348 incorporation Methods 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 108700005077 Viral Genes Proteins 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 238000001890 transfection Methods 0.000 claims description 5
- 108060003393 Granulin Proteins 0.000 claims description 4
- 101710172711 Structural protein Proteins 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 241001500351 Influenzavirus A Species 0.000 claims description 2
- -1 polymerase Proteins 0.000 claims description 2
- 241000714230 Avian leukemia virus Species 0.000 claims 1
- 241000700662 Fowlpox virus Species 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 77
- 239000007924 injection Substances 0.000 abstract description 77
- 230000000069 prophylactic effect Effects 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 192
- 241000699670 Mus sp. Species 0.000 description 188
- 108020004635 Complementary DNA Proteins 0.000 description 74
- 238000010804 cDNA synthesis Methods 0.000 description 74
- 239000002299 complementary DNA Substances 0.000 description 71
- 230000000692 anti-sense effect Effects 0.000 description 65
- 235000018102 proteins Nutrition 0.000 description 55
- 239000012634 fragment Substances 0.000 description 43
- 239000011148 porous material Substances 0.000 description 38
- 241000282339 Mustela Species 0.000 description 37
- 239000000047 product Substances 0.000 description 30
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 29
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 26
- 239000000427 antigen Substances 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 25
- 208000037797 influenza A Diseases 0.000 description 24
- 238000010968 computed tomography angiography Methods 0.000 description 23
- 238000003752 polymerase chain reaction Methods 0.000 description 23
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 20
- 230000004083 survival effect Effects 0.000 description 20
- 230000036039 immunity Effects 0.000 description 19
- 230000029142 excretion Effects 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 210000004989 spleen cell Anatomy 0.000 description 17
- 108010006025 bovine growth hormone Proteins 0.000 description 16
- 230000009089 cytolysis Effects 0.000 description 16
- 210000003205 muscle Anatomy 0.000 description 16
- 241000282693 Cercopithecidae Species 0.000 description 15
- 241000282412 Homo Species 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 230000004580 weight loss Effects 0.000 description 15
- 101150118742 NP gene Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 13
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 241000288906 Primates Species 0.000 description 12
- 102100037516 Protein polybromo-1 Human genes 0.000 description 12
- 101710085035 RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 229960003971 influenza vaccine Drugs 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 101710102873 Polymerase basic protein 2 Proteins 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 101150039660 HA gene Proteins 0.000 description 10
- 108010067390 Viral Proteins Proteins 0.000 description 10
- 210000003414 extremity Anatomy 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 9
- 102100029241 Influenza virus NS1A-binding protein Human genes 0.000 description 9
- 101710128560 Initiator protein NS1 Proteins 0.000 description 9
- 101710144127 Non-structural protein 1 Proteins 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000028996 humoral immune response Effects 0.000 description 9
- 210000000663 muscle cell Anatomy 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 230000002685 pulmonary effect Effects 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000035931 haemagglutination Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 108020000999 Viral RNA Proteins 0.000 description 7
- 238000010219 correlation analysis Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 210000003098 myoblast Anatomy 0.000 description 7
- 241000282552 Chlorocebus aethiops Species 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 230000024932 T cell mediated immunity Effects 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 229940021995 DNA vaccine Drugs 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 108091092724 Noncoding DNA Proteins 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 235000013882 gravy Nutrition 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 238000001823 molecular biology technique Methods 0.000 description 3
- 210000000107 myocyte Anatomy 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 238000012770 revaccination Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 101150076514 NS gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101150103639 PB1 gene Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 239000013026 undiluted sample Substances 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101150002210 34 gene Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241001209177 Akis Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000252870 H3N2 subtype Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 101150033828 NS1 gene Proteins 0.000 description 1
- 102000035028 Nucleic proteins Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 101150030427 PB2 gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- WHSQPVUDHQAQLA-UHFFFAOYSA-N SSSSSSSSSS Chemical compound SSSSSSSSSS WHSQPVUDHQAQLA-UHFFFAOYSA-N 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 101710165315 Sialidase A Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011832 ferret model Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000010359 gene isolation Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 229940033326 influenza DNA vaccine Drugs 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 101150027243 pb gene Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940031418 trivalent vaccine Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3238393A | 1993-03-18 | 1993-03-18 | |
| US8998593A | 1993-07-08 | 1993-07-08 | |
| PCT/US1994/002751 WO1994021797A1 (en) | 1993-03-18 | 1994-03-14 | Nucleic acid pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG100006A BG100006A (bg) | 1996-12-31 |
| BG63126B1 true BG63126B1 (bg) | 2001-04-30 |
Family
ID=26708344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG100006A BG63126B1 (bg) | 1993-03-18 | 1995-09-18 | Лечебни препарати на основата на нуклеинови киселини |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0620277A1 (cs) |
| JP (2) | JP2812352B2 (cs) |
| CN (1) | CN1119458A (cs) |
| AU (1) | AU676258B2 (cs) |
| BG (1) | BG63126B1 (cs) |
| BR (1) | BR9406007A (cs) |
| CA (1) | CA2119175A1 (cs) |
| CZ (1) | CZ290315B6 (cs) |
| DZ (1) | DZ1759A1 (cs) |
| FI (1) | FI954329A (cs) |
| HR (1) | HRP940175A2 (cs) |
| HU (1) | HUT73397A (cs) |
| IL (1) | IL108915A0 (cs) |
| NO (1) | NO953649L (cs) |
| NZ (1) | NZ263680A (cs) |
| PL (1) | PL178626B1 (cs) |
| RO (1) | RO117710B1 (cs) |
| SI (1) | SI9420014A (cs) |
| SK (1) | SK114295A3 (cs) |
| UA (1) | UA42715C2 (cs) |
| WO (1) | WO1994021797A1 (cs) |
| YU (1) | YU12894A (cs) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
| US6911216B1 (en) | 1994-10-12 | 2005-06-28 | Genzyme Corporation | Targeted delivery via biodegradable polymers |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| DE19512142A1 (de) * | 1995-03-31 | 1996-10-02 | Immuno Ag | Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält |
| US6019980A (en) | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| US6017897A (en) * | 1995-06-07 | 2000-01-25 | Pasteur Merieux Connaught Canada | Nucleic acid respiratory syncytial virus vaccines |
| US6083925A (en) * | 1995-06-07 | 2000-07-04 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
| FR2751225B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
| US6204250B1 (en) | 1996-11-22 | 2001-03-20 | The Mount Sinai Medical Center Of The City Of New York | Immunization of infants |
| ES2232934T3 (es) * | 1997-02-14 | 2005-06-01 | MERCK & CO., INC. | Formulaciones de vacunas a base de polinucleotidos. |
| US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
| UA78180C2 (uk) | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
| FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
| US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
| US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
| AU5366099A (en) | 1998-08-20 | 2000-03-14 | Connaught Laboratories Limited | Nucleic acid molecules encoding inclusion membrane protein of (chlamydia) |
| US6881723B1 (en) | 1998-11-05 | 2005-04-19 | Powderject Vaccines, Inc. | Nucleic acid constructs |
| US7618797B2 (en) | 1998-12-22 | 2009-11-17 | Pfizer Inc | Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
| US7691389B2 (en) | 1998-12-22 | 2010-04-06 | Pfizer Inc | Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
| WO2000047227A2 (en) | 1999-02-09 | 2000-08-17 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis, immunization |
| US6943152B1 (en) | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
| JP2001151698A (ja) * | 1999-09-10 | 2001-06-05 | Nichiko Pharmaceutical Co Ltd | インフルエンザワクチン |
| WO2001030382A1 (en) | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| US7196066B1 (en) | 1999-11-03 | 2007-03-27 | Powderject Vaccines, Inc. | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
| US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| US7078388B2 (en) | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| EP1792995A3 (en) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia secretory locus orf and uses thereof |
| ATE346925T1 (de) | 2000-05-10 | 2006-12-15 | Sanofi Pasteur Ltd | Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen |
| JP5331340B2 (ja) | 2004-05-18 | 2013-10-30 | バイカル インコーポレイテッド | インフルエンザウィルスワクチン組成物、及びその使用方法 |
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| AU2008260023A1 (en) * | 2007-05-31 | 2008-12-11 | Becton, Dickinson And Company | Sequences and methods for detecting influenza A and influenza B virus |
| US8354230B2 (en) * | 2007-12-21 | 2013-01-15 | Quest Diagnostics Investments Inc. | Multiplex detection assay for influenza and RSV viruses |
| RU2011107757A (ru) | 2008-08-01 | 2012-09-10 | Гамма Ваксинс Пти Лимитед (Au) | Вакцины против гриппа |
| CA2760553A1 (en) | 2009-04-30 | 2010-11-04 | Jr. James E. Crowe | Monoclonal antibodies to influenza h1n1 virus and uses thereof |
| SG168423A1 (en) * | 2009-07-13 | 2011-02-28 | Agency Science Tech & Res | Influenza detection method and kit therefor |
| AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
| AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
| AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| WO2013033092A2 (en) | 2011-09-03 | 2013-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Streptococcus suis pilus antigens |
| WO2013138118A1 (en) | 2012-03-14 | 2013-09-19 | The Regents Of The University Of California | Treatment of inflammatory disorders in non-human mammals |
| WO2014127825A1 (en) | 2013-02-21 | 2014-08-28 | Boehringer Ingelheim Vetmedica Gmbh | H5 proteins of h5n1 influenza virus for use as a medicament |
| RU2662667C2 (ru) * | 2013-03-18 | 2018-07-26 | Озивакс Сас | Вакцины на основе нуклеопротеина вируса гриппа |
| MX2016003855A (es) | 2013-09-25 | 2016-08-04 | Zoetis Services Llc | Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso. |
| EP3125932A1 (en) | 2014-04-03 | 2017-02-08 | Boehringer Ingelheim Vetmedica, Inc. | Porcine epidemic diarrhea virus vaccine |
| EA036116B1 (ru) | 2015-08-31 | 2020-09-30 | Берингер Ингельхайм Ветмедика Гмбх | Пестивирусные вакцины против врожденного тремора |
| WO2017048677A1 (en) | 2015-09-16 | 2017-03-23 | Boehringer Ingelheim Vetmedica, Inc. | Salmonella choleraesuis-salmonella typhimurium vaccines |
| EP3515504B1 (en) | 2016-09-20 | 2023-07-12 | Boehringer Ingelheim Vetmedica GmbH | Canine adenovirus vectors |
| EP3516064A1 (en) | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | New promoters |
| US10619169B2 (en) | 2016-09-20 | 2020-04-14 | Boehringer Ingelheim Vetmedica Gmbh | EHV insertion site ORF70 |
| MX2019003116A (es) | 2016-09-20 | 2019-08-29 | Boehringer Ingelheim Vetmedica Gmbh | Nueva vacuna contra la gripe porcina. |
| PT3534939T (pt) | 2016-11-03 | 2023-04-20 | Boehringer Ingelheim Vetmedica Gmbh | Vacina contra parvovírus porcino e vírus da síndrome reprodutiva e respiratória porcina e métodos da sua produção |
| UA127859C2 (uk) | 2016-11-03 | 2024-01-31 | Бьорінгер Інгельхайм Ветмедіка Гмбх | Вакцина проти свинячого парвовірусу |
| JP2020506915A (ja) | 2017-01-30 | 2020-03-05 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | ブタコロナウイルスワクチン |
| WO2019014144A1 (en) | 2017-07-12 | 2019-01-17 | Boehringer Ingelheim Vetmedica, Inc. | IMMUNOGENIC COMPOSITIONS BASED ON SENECAVIRUS TYPE A AND CORRESPONDING METHODS |
| BR112020005767A2 (pt) | 2017-09-23 | 2020-10-13 | Boehringer Ingelheim Vetmedica Gmbh | sistema de expressão de paramyxoviridae |
| WO2019092027A1 (en) | 2017-11-09 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Sapelovirus immunogenic compositions and uses thereof |
| BR112020017239A2 (pt) | 2018-02-23 | 2020-12-22 | Boehringer Ingelheim Vetmedica Gmbh | Sistemas de vetor viral recombinante que expressam genes de paramixovírus felino exógenos e vacinas feitas a partir deles |
| CA3091960A1 (en) | 2018-03-19 | 2019-09-26 | Boehringer Ingelheim Vetmedica Gmbh | New ehv insertion site ul43 |
| WO2019179998A1 (en) | 2018-03-19 | 2019-09-26 | Boehringer Ingelheim Vetmedica Gmbh | New ehv with inactivated ul18 and/or ul8 |
| WO2019191005A1 (en) | 2018-03-26 | 2019-10-03 | Boehringer Ingelheim Animal Health USA Inc. | Method of producing an immunogenic composition |
| EP3852800A1 (en) | 2018-09-20 | 2021-07-28 | Boehringer Ingelheim Vetmedica GmbH | Intranasal vector vaccine against porcine epidemic diarrhea |
| TW202027785A (zh) | 2018-09-20 | 2020-08-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 經修飾之pedv棘蛋白 |
| IT201900007060A1 (it) | 2019-05-21 | 2020-11-21 | St Superiore Di Sanita | Cellule tumorali ingegnerizzate e loro usi |
| IT201900012540A1 (it) | 2019-07-22 | 2021-01-22 | Humanitas Mirasole Spa | Inibitori di CHI3L1 e loro usi |
| US11858962B2 (en) | 2020-02-06 | 2024-01-02 | Boehringer Ingelheim Vetmedica Gmbh | Polypeptides useful for detecting anti-rhabdovirus antibodies |
| BR112023006274A2 (pt) | 2020-10-05 | 2023-05-09 | Boehringer Ingelheim Vetmedica Gmbh | Proteína de fusão útil para vacinação contra rotavírus |
| JP2023544403A (ja) | 2020-10-05 | 2023-10-23 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | サーコウイルス科カプシドタンパク質を含む融合タンパク質、及びそれから構成されるキメラウイルス様粒子 |
| WO2023194913A1 (en) | 2022-04-05 | 2023-10-12 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition useful for vaccination against rotavirus |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL86354A0 (en) * | 1987-05-22 | 1988-11-15 | Orion Yhtymae Oy | Episomal vector for the expression of selected dna fragments coding for optional polypeptides in mammalian cells and methods for the production thereof |
| DE69034168T3 (de) * | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
-
1994
- 1994-03-09 IL IL10891594A patent/IL108915A0/xx unknown
- 1994-03-09 EP EP94200605A patent/EP0620277A1/en not_active Withdrawn
- 1994-03-14 PL PL94310677A patent/PL178626B1/pl unknown
- 1994-03-14 RO RO95-01622A patent/RO117710B1/ro unknown
- 1994-03-14 CZ CZ19952373A patent/CZ290315B6/cs not_active IP Right Cessation
- 1994-03-14 CN CN94191485A patent/CN1119458A/zh active Pending
- 1994-03-14 HU HU9502702A patent/HUT73397A/hu unknown
- 1994-03-14 WO PCT/US1994/002751 patent/WO1994021797A1/en active IP Right Grant
- 1994-03-14 BR BR9406007A patent/BR9406007A/pt not_active Application Discontinuation
- 1994-03-14 SK SK1142-95A patent/SK114295A3/sk unknown
- 1994-03-14 SI SI9420014A patent/SI9420014A/sl not_active IP Right Cessation
- 1994-03-14 UA UA95094152A patent/UA42715C2/uk unknown
- 1994-03-14 NZ NZ263680A patent/NZ263680A/en unknown
- 1994-03-16 DZ DZ940021A patent/DZ1759A1/fr active
- 1994-03-16 CA CA002119175A patent/CA2119175A1/en not_active Abandoned
- 1994-03-17 AU AU57889/94A patent/AU676258B2/en not_active Ceased
- 1994-03-17 YU YU12894A patent/YU12894A/sh unknown
- 1994-03-17 HR HR08/089,985A patent/HRP940175A2/xx not_active Application Discontinuation
- 1994-03-18 JP JP6049102A patent/JP2812352B2/ja not_active Expired - Fee Related
-
1995
- 1995-09-14 FI FI954329A patent/FI954329A/fi unknown
- 1995-09-15 NO NO953649A patent/NO953649L/no not_active Application Discontinuation
- 1995-09-18 BG BG100006A patent/BG63126B1/bg unknown
-
1997
- 1997-10-22 JP JP29013797A patent/JP3608642B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994021797A1 (en) | 1994-09-29 |
| PL310677A1 (en) | 1995-12-27 |
| SI9420014A (en) | 1996-08-31 |
| HRP940175A2 (en) | 1997-04-30 |
| AU5788994A (en) | 1994-09-22 |
| NO953649D0 (no) | 1995-09-15 |
| DZ1759A1 (fr) | 2002-02-17 |
| UA42715C2 (uk) | 2001-11-15 |
| JPH10113194A (ja) | 1998-05-06 |
| CZ290315B6 (cs) | 2002-07-17 |
| AU676258B2 (en) | 1997-03-06 |
| FI954329A0 (fi) | 1995-09-14 |
| RO117710B1 (ro) | 2002-06-28 |
| PL178626B1 (pl) | 2000-05-31 |
| BG100006A (bg) | 1996-12-31 |
| YU12894A (sh) | 1997-12-05 |
| HU9502702D0 (en) | 1995-11-28 |
| IL108915A0 (en) | 1994-06-24 |
| CN1119458A (zh) | 1996-03-27 |
| JPH0795888A (ja) | 1995-04-11 |
| CA2119175A1 (en) | 1994-09-19 |
| JP3608642B2 (ja) | 2005-01-12 |
| SK114295A3 (en) | 1996-02-07 |
| NZ263680A (en) | 1997-05-26 |
| FI954329A (fi) | 1995-09-14 |
| HUT73397A (en) | 1996-07-29 |
| NO953649L (no) | 1995-11-17 |
| JP2812352B2 (ja) | 1998-10-22 |
| CZ237395A3 (en) | 1996-02-14 |
| BR9406007A (pt) | 1996-01-02 |
| EP0620277A1 (en) | 1994-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU676258B2 (en) | Nucleic acid pharmaceuticals | |
| AU734690B2 (en) | Coordinate in vivo gene expression | |
| CA2482946C (en) | Multi plasmid system for the production of influenza virus | |
| US6534312B1 (en) | Vaccines comprising synthetic genes | |
| KR102557390B1 (ko) | 비-구조 단백질의 단편으로 구성된 뎅기 바이러스 키메라 폴리에피토프 및 이의 뎅기 바이러스 감염에 대한 면역원성 조성물에서의 용도 | |
| US20040087521A1 (en) | Nucleic acid pharmaceuticals-influenza matrix | |
| HUE025727T2 (en) | Multi-plasmid system for producing influenza virus | |
| CN115867561A (zh) | SARS-CoV蛋白、核酸构建体、病毒样蛋白(VLP)的表达及其相关方法 | |
| CN116113427A (zh) | 天然外膜囊泡中的sars-cov-2受体结合结构域 | |
| CA2842055C (en) | Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene | |
| US10894080B2 (en) | Transgenic VERO-CD4/CCR5 cell line | |
| AU3723099A (en) | Attenuated influenza viruses | |
| RU2193065C2 (ru) | Конструкция днк (варианты), днк-вектор, иммуногенная композиция против вируса гриппа, способ индукции иммунного ответа, вакцина и способ вакцинации | |
| MXPA01010481A (es) | Acidos nucleicos y polipeptidos de lisavirus quimerico. | |
| US9925258B2 (en) | Replication-competent VSV-HIV Env vaccines | |
| WO2023057766A1 (en) | Influenza vaccines | |
| Song et al. | Recombinant influenza viruses as delivery vectors for hepatis B virus epitopes |